Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portola ready to go it alone after Merck bows out of factor Xa partnership

This article was originally published in Scrip

Executive Summary

Portola Pharmaceuticals CEO William Lis said Merck's decision to return the rights to his firm for betrixaban, an investigational oral factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation, came as no surprise, insisting that the companies had been in discussions for awhile about the smaller biotech independently taking the drug forward.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012372

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel